The Safety and Pharmacokinetics of ASKC200 in Osteoarthritic Knee Pain

Study acronym: ASKC200
StatusUnknown
PhasePhase 1
Started

Record status This record was last updated September 27, 2024 (before its estimated April 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
  2. Secondary endpoints: details revised at 2 of 8 entries
    • Study title shortened, about 6 words
    v2
  3. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multi-center, randomized, double-blind clinical trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASKC200 in subjects with OA of the knees and determine the phase II recommended dose. Assigned doses will be applied for 60 minutes on each of four consecutive days.
Trial Details
NCT Number NCT06614608
Lead Sponsor Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Osteoarthritis, Knee, Pain
Related terms Osteoarthritis, Knee, Pain
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov